ClinicalTrials.gg
CompletedNCT01906372Updated Sep 1, 2017Results posted

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

A Phase 2 interventional study of Adrenocorticotropic Hormone Gel in Dermatomyositis and Polymyositis, sponsored by Rohit Aggarwal, MD. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Rohit Aggarwal, MD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Dermatomyositis with a site in United States — 29 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.

Enrollment
55th of 73
12 · median 25
Started
2013
with 3 others
Phase 2
31 of 94
5 open now
Registered
28th of 94
by date

Among the 94 studies in Dermatomyositis with a site in United States, this one is the 55th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2013, is one of 31 in phase 2, and was the 28th registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 62 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

29 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Dermatomyositis studies recruiting now, 24 (49%) set no upper age limit and 15 (31%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Dermatomyositis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is associated with a rash (DM) or polymyositis (PM) a disease that causes muscle weakness without a rash. The study doctors want to evaluate whether ACTH Gel will improve the symptoms of this disease. This drug is approved by the Food and Drug Administration (FDA) for dermatomyositis (DM) and polymyositis (PM). ACTH gel has been an FDA-approved treatment for myositis since 1952, and in 2010 the FDA retained PM and DM as diseases approved for ACTH gel use.

Read the detailed description

Despite its FDA approval there is very limited data on its clinical effectiveness in PM and DM. There was a recent study published in the peer-review journal Drug Design, Development and Therapy on a retrospective case series evaluating Acthar in the treatment of PM and DM. Acthar was administered to five patients who had previously failed multiple steroid and immunosuppressant treatment regimens. The patients received injections of Acthar over the course of 12 weeks or more. Improvement in PM and DM symptoms related to disease exacerbations was seen in all five patients. Symptom improvements included increased muscle strength, resolution of disease-related skin manifestations and improvements in the ability to perform tasks associated with daily living. All of these patients tolerated the treatment well with no significant side effects reported. The paper, "Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series," was authored by Dr. Todd Levine, M.D., Co-Director of the Neurophysiology Department at Banner Good Samaritan Medical Center, Assistant Professor at the University of Arizona in Neurology, and Member of Phoenix Neurological Associates.

H.P. Acthar® Gel, or Acthar, is a prescription medication containing the hormone adrenocorticotropin (hormone produced and secreted by the anterior pituitary gland), also known as ACTH. H.P. Acthar Gel is a highly purified preparation of adrenocorticotropic hormone (ACTH) in a gel that is designed to provide extended release of the ACTH following injection. Acthar was originally approved by the FDA in 1952. It is approved for use in 19 different conditions including dermatomyositis and polymyositis.

Acthar is designed to provide a prolonged release of the medication after it is injected. Acthar is not a steroid; it works by helping your body produce its own natural steroid hormones, such as cortisol, corticosterone, and aldosterone. Acthar is an injection that is given intramuscularly (into the muscle). Subjects enrolled in the study will be asked to self administer Acthar two times per week. Subjects will be provided training by the principal investigator on how to perform the self injections.

03

Conditions studied

  • Dermatomyositis
  • Polymyositis

Keywords

  • dermatomyositis
  • polymyositis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definite or probable polymyositis (PM) or dermatomyositis (DM) by Bohan and Peter criteria.
  • PM patients must either possess a myositis-associated autoantibody or undergo adjudication for confirmation of the PM diagnosis by consensus of two experts to ensure non-PM patients are not enrolled. This step is necessary since there are well-known mimics of PM.
  • Age ≥ 18 years.
  • Active myositis as defined by baseline Manual Muscle Testing (MMT-8) no greater than 125/150 and at least 2 additional CSM meeting the criteria stipulated below:

    1. Patient global with a minimum value of 2.0 cm on a 10 cm visual analog scale(VAS)
    2. Physician global with a minimum value of 2.0 cm on a 10 cm VAS scale
    3. Health Assessment Questionnaire (HAQ) disability index with a minimum value of 0.25
    4. Elevation of at least one of the muscle enzymes [which includes creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), (ALT) and aspartate aminotransferase (AST)] at a minimum level of 1.3 x the .
    5. Global extramuscular disease activity score with a minimum value of 1.0 cm on a 10 cm VAS scale [this measure is the physician's composite evaluation and is based on assessments of activity scores on the constitutional, cutaneous, skeletal, gastrointestinal, pulmonary and cardiac scales of the Myositis Disease Activity Assessment Tool (MDAAT)].
  • To ensure that we can enroll active DM patients with a severe rash who may not meet the MMT-8 criterion noted above, we propose additional enrollment criteria such that the International Myositis Assessment and Clinical Studies (IMACS) definition of improvement (DOI) can potentially be met:

    1. Cutaneous VAS score on MDAAT > 3 cm on a 10 cm VAS scale, and
    2. At least 3 of the above 5 (a through e under 4.) criteria.
  • myositis is defined by active disease despite an adequate trial (> 2 months of usual glucocorticoid therapy or intolerance to such therapy) and/or ≥ 1 conventional agent (e.g. methotrexate, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil, IVIG, anti-TNF or rituximab) for a reasonable dose and duration (> 3 months or intolerance to therapy). It is recommended to enroll refractory patients failing (or intolerant to) both glucocorticoids and at least 1 conventional immunosuppressive agent.
  • If the enrolling physician is planning to continue current immunosuppressive agents or glucocorticoids as concomitant therapy with Acthar gel during the trial, then patient must be on a stable glucocorticoid and/or immunosuppressive dose 2 weeks prior to visit 1. The patient should have been on that immunosuppressive medication for at least 8 weeks (and at least 4 weeks for glucocorticoids) prior to visit 1.
  • If the enrolling physician is planning to discontinue current immunosuppressive agent or glucocorticoids, then following wash out period is required prior to visit 1.
  • If previous concomitant medications were discontinued, the following wash out periods are required prior to Visit 1
  • Methotrexate -4 weeks
  • Other IS agent (e.g. azathioprine, cyclosporine, tacrolimus, leflunomide, mycophenolate mofetil) - 4 weeks
  • IVIg or cyclophosphamide - 2 months
  • rituximab -6 months
  • infliximab or adalimumab -8 weeks
  • glucocorticoids - 2 weeks
  • etanercept -2 weeks
  • anakinra -1 week

Exclusion criteria

Exclusion Criteria:

  • Juvenile DM or PM, myositis in overlap with another connective tissue disease, cancer associated myositis, inclusion body myositis, or any other non immune-mediated myopathy.
  • to Acthar
  • Severe cardiac or pulmonary involvement
  • Severe muscle damage defined as a baseline global muscle damage score on the MDI (Myositis Damage Index) of ≥ 5 cm on a 10 cm VAS.
  • Patients with within 3 years of screening (except basal cell cancer or squamous cell cancer of skin).
  • Uncontrolled diabetes, hepatic or renal disease.
  • Ongoing active or chronic infections.
  • Pregnant or lactating females.
  • For any medical or physical or socio-psychological reasons that PI feels would not allow the subject to complete the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Acthar Gel

    Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.

    Drug: Adrenocorticotropic Hormone Gel

Interventions

06

What researchers measure

Primary outcomes

  1. Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI).

    3 of any of the 6 core set measures (CSM) improved by ≥ 20%, with no more than 2 CSM worsening by ≥25% (worsening measure cannot include the MMT). The DOI should be met at least once on any of the 6 follow up visits and maintained until week 24. Subjects not meeting DOI during the trial are treatment failures.

    Time frame: Primary end point: IMACS preliminary definition of improvement (DOI)

Secondary outcomes

  1. Steroid-sparing Effect of H.P. Acthar Gel in Refractory Adult PM and DM Patients.

    Mean change in glucocorticoid dose (equivalent prednisone dose) at 24 weeks compared to baseline.

    Time frame: Steroid sparing effect and safety and tolerability at 24 weeks compared to baseline

07

Results

Posted Aug 2, 2017
Limitations and caveats
Small pilot open label single arm trial. Larger double blinded placebo controlled randomized trials are required.

Participant flow

Subjects with active and refractory polymyositis or dermatomyositis were recruited at two clinical centers, The University of Pittsburgh and North Shore Long Island Jewish Center over a 16 month recruitment period. Two subjects did not reach the week 8 time point prior to withdrawing from the trial therefore additional subjects were enrolled.

Participant flow — Overall Study
MilestoneActhar Gel
Started12
Visit 7: treatment phase completed10
Visit 10: follow up phase completed8
Completed10
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimarySpecific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI).

3 of any of the 6 core set measures (CSM) improved by ≥ 20%, with no more than 2 CSM worsening by ≥25% (worsening measure cannot include the MMT). The DOI should be met at least once on any of the 6 follow up visits and maintained until week 24. Subjects not meeting DOI during the trial are treatment failures.

Time frame:
Primary end point: IMACS preliminary definition of improvement (DOI)
Reported as:
Count of participants · Participants
Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI).
ParticipantsActhar Gel
Specific Aim 1: Number of Subjects Meeting IMACS Preliminary Definition of Improvement (DOI).7
Statistical analysis
  • Acthar Gel · Frequency of achieving primary endpoint: 0.70
SecondarySteroid-sparing Effect of H.P. Acthar Gel in Refractory Adult PM and DM Patients.

Mean change in glucocorticoid dose (equivalent prednisone dose) at 24 weeks compared to baseline.

Time frame:
Steroid sparing effect and safety and tolerability at 24 weeks compared to baseline
Reported as:
Mean · mg
Steroid-sparing Effect of H.P. Acthar Gel in Refractory Adult PM and DM Patients.
mgActhar Gel
Follow Up 24 weeks2.3 ± 3.2
Baseline18.5 ± 15.7
Statistical analysis
  • Acthar Gel · t-test, 2 sided · p = <0.01

Adverse events

Collected over Adverse events were collected during the overall duration of the study (12 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acthar Gel—3/10 (30%)7/10 (70%)
Most frequent serious events
Most frequent serious events
EventActhar Gel
Local infection with moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, aInfections and infestations2/10
Avascular NecrosisMusculoskeletal and connective tissue disorders1/10
Atrioventricular BlockCardiac disorders1/10
Non-cardiac chest painGeneral disorders1/10
Most frequent other events
Showing 10 of 14
Most frequent other events
EventActhar Gel
General disorders and administration site conditionsGeneral disorders4/10
HyperglycemiaMetabolism and nutrition disorders3/10
InsomniaPsychiatric disorders2/10
CalcinosisSkin and subcutaneous tissue disorders2/10
HypertensionVascular disorders2/10
Sinus TachycardiaCardiac disorders1/10
DiarrheaGastrointestinal disorders1/10
SinusitisInfections and infestations1/10
Upper Respiratory InfectionsInfections and infestations1/10
Cholesterol highMetabolism and nutrition disorders1/10

Baseline characteristics

A total of 12 participants were enrolled however only 11 participants were assessed for baseline characteristics due to one subject withdrawing after screening and never received study drug.

Age, Categorical
Age, Categorical(Participants)Acthar Gel
<=18 years0
Between 18 and 65 years10
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Acthar Gel
Female10
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acthar Gel
Hispanic or Latino2
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Acthar Gel
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American5
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Acthar Gel
United States11
Diagnosis
Diagnosis(Participants)Acthar Gel
Dermatomyositis6
Polymyositis5
Disease Duration
Disease Duration(years)Acthar Gel
Mean2.0 ± 2.0
Autoantibody Status
Autoantibody Status(Participants)Acthar Gel
Count of participants8
08

Study locations

2 sites
  • North Shore LIJ Medical Center
    Great Neck, New York 11021, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
09

References and documents

Publications

  • Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004 Mar;56(1):1-29. doi: 10.1124/pr.56.1.1. PubMed 15001661 ↗
  • Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. ScientificWorldJournal. 2010 Sep 14;10:1840-53. doi: 10.1100/tsw.2010.173. PubMed 20852827 ↗
  • Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996 Mar;97(3):375-9. PubMed 8604274 ↗
  • Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, Radhakrishnan J, Appel GB. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011 Mar 14;5:147-53. doi: 10.2147/DDDT.S17521. PubMed 21448451 ↗
  • Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther. 2011;5:381-9. doi: 10.2147/DDDT.S19331. Epub 2011 Jul 11. PubMed 21792296 ↗
  • Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133-9. doi: 10.2147/DDDT.S33110. Epub 2012 Jun 11. Erratum In: Drug Des Devel Ther. 2012;6:163. PubMed 22787386 ↗
  • Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW; International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004 Jul;50(7):2281-90. doi: 10.1002/art.20349. PubMed 15248228 ↗
  • Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754. PubMed 23124935 ↗
  • Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018 May;77(5):720-727. doi: 10.1136/annrheumdis-2017-212047. Epub 2017 Dec 13. PubMed 29237618 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Sep 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2013
First posted
Jul 24, 2013
Start
Sep 2013
Primary completionActual
Sep 2015
CompletionActual
May 2016
Results first posted
Aug 2, 2017
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01906372
Lead sponsor
Rohit Aggarwal, MD
Collaborators
Mallinckrodt
Responsible party
Rohit Aggarwal, MD (Assistant Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Jul 24, 2013
Start date
Sep 2013
Primary completion
Sep 2015
Completion
May 2016
Results posted
Aug 2, 2017
Last update
Sep 1, 2017

Study contacts

Rohit Aggarwal, MD
principal investigator · University of Pittsburgh, Division of Rheumatology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adrenocorticotropic Hormone

Start the discussion